What is Polpharma?
Headquartered in Starogard Gdański, Polpharma operates as a premier pharmaceutical manufacturer, specializing in the development and production of high-quality medicinal products. The company maintains a robust market position by integrating advanced manufacturing processes with a deep commitment to therapeutic innovation. By focusing on both generic and specialized pharmaceutical solutions, Polpharma serves as a critical link in the regional supply chain, ensuring that essential healthcare products remain accessible while adhering to stringent international quality standards. Its operational model is characterized by a blend of traditional pharmaceutical expertise and modern industrial efficiency, positioning the firm as a leader in the Central and Eastern European life sciences sector.
How much funding has Polpharma raised?
Polpharma has raised a total of $50.3M across 1 funding round:
Debt
$50.3M
Debt (2015): $50.3M with participation from European Investment Bank
Key Investors in Polpharma
European Investment Bank
The European Investment Bank Group focuses on investing in people and ideas to enhance education, social resilience, and partnerships, supporting projects that contribute to Europe's competitiveness and inclusive growth.
What's next for Polpharma?
With this major enterprise-level funding, Polpharma is well-positioned to accelerate its strategic growth initiatives. The capital is expected to facilitate the modernization of manufacturing facilities and the potential expansion of its research and development pipeline. As the company navigates the complexities of the global pharmaceutical market, this financial backing provides the necessary stability to pursue long-term sustainability goals and enhance its competitive edge. Future efforts will likely focus on scaling production capacity to meet rising demand and exploring new therapeutic areas that align with the company's core competencies in pharmaceutical manufacturing and distribution.
See full Polpharma company page